💊 On an SGLT2 Inhibitor

What this panel can settle, and by what logic

Nine markers for a drug class whose four commonest laboratory findings are all read wrongly at least some of the time.

1. The early fall in filtration is the mechanism of the kidney protection, not a side effect. Filtration drops in the first weeks because intraglomerular pressure is being reduced, then stabilizes and declines more slowly thereafter. Practical prescribing guidance for this class in chronic kidney disease treats that dip as expected and as a reason to continue rather than stop Yau 2022. This panel measures it with Cystatin C with eGFR as well as creatinine because the two disagree systematically in muscular people Wang 2023.
2. Glucose in the Urinalysis, Routine is the drug working. It will be positive in essentially everyone on this class and it is not evidence that diabetes is uncontrolled. What the urine is still worth reading for is protein, which should be falling Beernink 2025.
3. The Complete Blood Count (CBC) with Differential catches a hematocrit rise whose cause is genuinely argued about. Part appears to be hemoconcentration from diuresis and part appears to be increased erythropoiesis after improved renal cortical oxygenation; the two hypotheses have been set against each other explicitly Ekanayake 2023. Either way it adds to any other erythropoietic exposure, which is why a baseline matters in anyone also on testosterone or with untreated sleep apnea Gangat 2025.
4. Uric Acid falls on this class through the same glucose transporter mechanism that produces the glucosuria, and drug effects on urate transport are documented as a class of interaction in their own right Tatrai 2021. If gout is in the picture that is a real advantage.
5. Magnesium (Serum) shifts on this class, generally upward, and it costs thirteen dollars to watch.
6. The bicarbonate on the Comprehensive Metabolic Panel (CMP) is the number that matters if ketones ever become a question Bitar 2022.

What it cannot settle, and what would

It cannot tell you whether you are in ketoacidosis, and this is the one that can kill somebody. The serious adverse event with this class is euglycemic diabetic ketoacidosis: acidosis at a NORMAL blood glucose, which is why it is missed Bitar 2022. The test is a blood ketone measurement, it is not in this catalog, and it is not something to wait for a laboratory to run. Nausea, vomiting, abdominal pain, deep rapid breathing or confusion on an SGLT2 inhibitor is an emergency whatever your glucose meter says.

It cannot separate hemoconcentration from real erythropoiesis. That distinction requires a red cell mass study, and the mechanism remains an open question Ekanayake 2023.

It cannot detect a genital fungal infection, which is the common nuisance side effect of putting sugar in the urine and is diagnosed by looking rather than by testing.

And a single filtration measurement cannot tell you whether the trajectory is good. The whole value of this class is in the slope over years, so two points 12 months apart say more than one point ever will Yau 2022.

Draw conditions that decide whether the money is wasted

Four conditions, and the first prevents the commonest false alarm.

1. Not within 4 weeks of starting or of a dose change. The early filtration dip has not stabilized, and a draw taken inside that window gets read as harm Yau 2022.
2. Come properly hydrated. This class is a mild diuretic and a dehydrated draw exaggerates both the hematocrit and the creatinine Ekanayake 2023.
3. Fast 9 to 12 hours and take the drug as usual. The point is to measure the treated state.
4. Say on the requisition if you have been vomiting, fasting, unwell or eating very low carbohydrate. That combination is precisely when ketoacidosis occurs on this class, and it occurs at a normal glucose Bitar 2022.

How you would know it answered your question, and what each pattern means next

Four patterns, and what the follow-up draw should show.

• A small fall in Cystatin C with eGFR filtration at 4 to 12 weeks that then holds: expected and desirable. The confirmation is stability at 6 to 12 months, not recovery at 4 weeks Yau 2022.
• A continuing fall across two later draws: not expected. That belongs with a clinician Yau 2022.
• Glucose positive with protein falling on the Urinalysis, Routine: the drug is doing both jobs, and the protein is the one that predicts outcome Beernink 2025.
• Hematocrit up with a low Ferritin or a large rise: treat it as any other erythrocytosis and look for the additional driver rather than assuming the drug explains all of it Ekanayake 2023Gangat 2025.

Sources read for these sections

• Yau K, et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports 2022 · PMID 35812300
• Ekanayake P, et al. Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?. Diabetes and Metabolic Syndrome 2023 · PMID 36657305
• Bitar ZI, et al. Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature. Clinical Case Reports 2022 · PMID 35169474
• Wang Y, et al. Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR. Kidney Medicine 2023 · PMID 37753251
• Beernink JM, et al. Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease. Diabetes Obesity and Metabolism 2025 · PMID 40143452
• Tatrai P, et al. Modulation of Urate Transport by Drugs. Pharmaceutics 2021 · PMID 34204277
• Gangat N, et al. JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management. American Journal of Hematology 2025 · PMID 41123216